Monitor Q3 2026 earnings for initial ThermAffyx revenue and hospital adoption metrics. The 510(k) clearance is a positive catalyst for Gentherm's medical segment, but the stock's primary driver remains automotive thermal management. Watch for updates on hospital trial results and any subsequent partnership announcements.
Price Chart
Executive Summary
Gentherm received FDA 510(k) clearance for its ThermAffyx Patient Safety System, a Class II medical device combining active patient warming, securement, and pressure reduction for robotic-assisted surgeries. Revenue generation is expected to begin in Q3 2026, with product trials starting in August. This expands Gentherm's medical portfolio beyond automotive thermal management, but the near-term financial impact is modest relative to the company's ~$1.5B annual revenue base.
Key Financial Metrics
Key Facts
- FDA 510(k) clearance for ThermAffyx Patient Safety System, a Class II medical device
- Device combines active patient warming, securement, and pressure reduction for robotic-assisted surgeries
- Product trials begin August 2026; revenue expected to commence in Q3 2026
- Addresses a gap where only 17-21% of patient body surface area is available for forced-air warming in robotic procedures
- Gentherm's 2025 annual sales were approximately $1.5 billion, with $2.2 billion in automotive new business awards
Financial Impact
Revenue generation expected to begin Q3 2026; near-term contribution modest relative to ~$1.5B annual sales
Risk Factors
- Commercial adoption may be slower than expected in the competitive hospital market
- Revenue contribution likely immaterial in the near term relative to automotive segment
- No disclosed pricing or volume commitments from healthcare facilities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330082 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $38.85 $36.35 | ▼ −6.43% | ▼ −6.21% | $31.30 (−19.43%) |
Sep 10, 2026 22d ago | Press Release | $38.33 $37.66 | ▼ −1.75% | ▼ −1.25% | $31.30 (−18.34%) |
Aug 13, 2026 7w ago | EFFECT | $43.07 $40.67 | ▼ −5.57% | ▼ −3.61% | $31.30 (−27.33%) |
Jul 23, 2026 10w ago | 425 / 8-K | $45.61 $42.32 | ▼ −7.21% | ▼ −7.69% | $31.30 (−31.37%) |
Jul 23, 2026 10w ago | Press Release | $45.61 $42.32 | ▼ −7.21% | ▼ −7.69% | $31.30 (−31.37%) |
Jul 22, 2026 10w ago | Press Release | $45.61 $42.32 | ▼ −7.21% | ▼ −7.69% | $31.30 (−31.37%) |
Jul 20, 2026 10w ago | Press Release | $36.64 $42.07 | ▲ +14.82% | ▲ +16.05% | $31.30 (−14.57%) |
Jul 7, 2026 12w ago | Press Release | $34.48 $35.89 | ▲ +4.09% | ▲ +3.23% | $31.30 (−9.22%) |
Jul 2, 2026 13w ago | 425 | $33.88 $35.68 | ▲ +5.31% | ▲ +4.38% | $31.30 (−7.62%) |
Jul 2, 2026 13w ago | 8-K | $33.88 $35.68 | ▲ +5.31% | ▲ +4.38% | $31.30 (−7.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access